Abstract
In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.
Original language | English (US) |
---|---|
Pages (from-to) | 216-218 |
Number of pages | 3 |
Journal | Tropical Doctor |
Volume | 51 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- HIV
- Tuberculosis
- dolutegravir
- immune reconstitution inflammatory syndrome
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases